36 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
and their impact on Adaptimmune’s and TCR2’s respective businesses, operations, supply chain, patient enrollment and retention, preclinical and clinical trials
425
TCRR
Tcr2 Therapeutics Inc
30 May 23
Business combination disclosure
4:21pm
health crises and their impact on Adaptimmune’s and TCR2’s respective businesses, operations, supply chain, patient enrollment and retention
8-K
i5m8ia6azn rt6ipjsli
30 May 23
Submission of Matters to a Vote of Security Holders
4:18pm
425
jq34w77oy7fi58q7
22 May 23
Business combination disclosure
7:01am
8-K
qk0 x3zmk
22 May 23
Other Events
6:59am
8-K
EX-99.1
yrz k9pi4d907gx6dof
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
424B3
pclb4iw9mb d4sf
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
j20 i9hwi
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
8-K
EX-10.1
b9z45qtw
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am
S-4
l2agf1qcv49m3jhy7hd0
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm